News Releases

Aug 04, 2022
Biodesix Announces Second Quarter 2022 Results and Highlights
Second quarter 2022 core Lung Diagnostic revenue of $7.3 million increased 52% over the comparable period in 2021; Received Medicare coverage for the Nodify CDT® Lung Nodule Test; Announced strategic arrangements during the quarter (Royal Philips, Memorial Sloan Kettering Cancer Center and
Aug 03, 2022
Biodesix to Present at the Canaccord Genuity 42nd Annual Growth Conference
BOULDER, Colo. --(BUSINESS WIRE)--Aug. 3, 2022-- Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced Scott Hutton , Chief Executive Officer of Biodesix , will present at the Canaccord Genuity 42nd Annual Growth Conference
Jul 20, 2022
Biodesix to Present Data at IASLC 2022 World Conference Demonstrating that the VeriStrat® Test is Predictive of Progression Free Survival and Overall Survival in Patients with Low or Negative PD-L1 Treated with Immune Checkpoint Inhibitors
New data emphasizes the utility of the VeriStrat ® Proteomic Test to identify patients likely to benefit from Immune Checkpoint Inhibitors BOULDER, Colo. --(BUSINESS WIRE)--Jul. 20, 2022-- Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung
Jul 19, 2022
Biodesix to Report Second Quarter 2022 Financial Results on August 4, 2022
BOULDER, Colo. --(BUSINESS WIRE)--Jul. 19, 2022-- Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus on lung disease, today announced that it will release financial results for the second quarter ended June 30, 2022 before the open of trading on Thursday,
Jun 07, 2022
Biodesix Obtains Medicare Coverage for the Nodify CDT® Lung Nodule Test
BOULDER, Colo. --(BUSINESS WIRE)--Jun. 7, 2022-- Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced that WPS Government Health Administrators, the Medicare Administrative Contractor with jurisdiction for Biodesix’s De Soto,
Jun 03, 2022
Biodesix Announces Research Agreement with Top US Cancer Center
Aim is to develop and commercialize new pipeline oncology biomarker assay in collaboration with Memorial Sloan Kettering Cancer Center and Bio-Rad, Inc. BOULDER, Colo. --(BUSINESS WIRE)--Jun. 3, 2022-- Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in
Jun 01, 2022
Biodesix to Present at the 42nd Annual William Blair Growth Stock Conference
BOULDER, Colo. --(BUSINESS WIRE)--Jun. 1, 2022-- Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced Scott Hutton , Chief Executive Officer of Biodesix , will present at the 42nd Annual William Blair Growth Stock Conference
Displaying 1 - 10 of 24